This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignees: Neurolixis, Uniwersytet Jagiellonski Collegium Medicum. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 3 
1 out of 1 Years Active: 2021
Title: Innovations by Anna Wesolowska: Pioneering Treatments for CNS Disorders
Introduction
Anna Wesolowska, an innovative inventor based in Cracow, Poland, has made significant contributions to the field of neuroscience. With one patented invention to her name, she has focused on developing treatments that address the side effects of existing therapies used to treat central nervous system (CNS) disorders. Her work is pivotal for improving patient care and enhancing quality of life for those affected by these conditions.
Latest Patents
Anna's patent titled "Use of selective serotonin 5-HT receptor agonists for treating side-effects of VMAT inhibitors" addresses the reduction of adverse effects caused by patients using tetrabenazine or other inhibitors of vesicular monoamine transporter (VMAT). This groundbreaking invention provides a solution for treating side effects related to various CNS disorders, including Huntington's disease, Parkinson's disease, Tourette's syndrome, and tardive dyskinesia. By administering an effective amount of selective serotonin 5-HT receptor agonists, the side effects of depression or Parkinsonism that may arise from VMAT inhibitor treatments can be minimized, thereby offering hope to many patients.
Career Highlights
Throughout her career, Anna has worked with prominent institutions, including Neurolixis and Jagiellonian University Medical College. Her experience in these organizations has allowed her to collaborate with leading experts in the field and gain insights that have shaped her innovative approaches to CNS disorder treatments.
Collaborations
Anna has collaborated with key figures including Magdalena Jastrzebska-Wiesek and Adrian Newman-Tancredi. These partnerships have been essential in advancing her research and ensuring her patented innovation could effectively reach those in need.
Conclusion
Anna Wesolowska's dedication to improving therapeutic options for patients suffering from central nervous system disorders is commendable. Her patented innovation not only underlines her inventiveness but also serves as an avenue for enhancing treatment strategies in the medical field. As research and development continue, her contributions hold the potential for even more significant advancements in patient care and efficacy in therapeutic practices.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile